Oral ciprofloxacin treatment for Salmonella typhimurium infection of normal and immunocompromised mice

Brünner, Helmut; Zeiler, H.-J.

doi:10.1128/aac.32.1.57

Cited by 18 publications

(10 citation statements)

References 42 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our experiments, treated BALB/c mice did not have relapses after 5 days of treatment. The in vitro MIC for our S. dublin strain was comparable to the MIC for the S. typhimunium strain used in the earlier study (5). However, in mice S. typhimurium is more virulent than S. dublin, which may account for the increased efficacy of ciprofloxacin in our study (27).…”

Section: Discussioncontrasting

confidence: 48%

See 1 more Smart Citation

Liposome-incorporated ciprofloxacin in treatment of murine salmonellosis

Magallanes

Dijkstra

Fierer

1993

Antimicrob Agents Chemother

View full text Add to dashboard Cite

We used a dehydration-rehydration procedure in order to efficiently incorporate ciprofloxacin into phospholipid vesicles (liposomes), which we then used to treat BALB/c mice that had been infected per os with SalmoneUla dublin. A single inijection of liposome-incorporated ciprofloxacin (LIC) was 10 times more effective than a single inijection of free drug at preventing mortality. When (3,8,9,12,14,26). In general, the liposomeincorporated antibiotics have proven superior to the plain form of the drugs (21).Ciprofloxacin is a quinolone antibiotic that has excellent in vitro activity against Salmonella species (13). It has been used in the treatment of individuals with Salmonella infections, including those with typhoid fever and chronic typhoid carriers (19,25). In previously published studies of animal models of S. typhimunum infection, both oral and subcutaneous administration of ciprofloxacin resulted in prolongation of survival and reductions in bacterial counts in liver and spleen compared with those in untreated controls and those after treatment with either ampicillin or chloramphenicol (5).In the study described here, we investigated the therapeutic value of liposome-incorporated ciprofloxacin (LIC) in a murine model of fatal S. dublin infection. Untreated, the infection begins in Peyer's patches, spreads to the regional lymph nodes, and then disseminates to the liver and spleen, * Corresponding author.leading to bacteremia and death 10 to 14 days after infection (16). In essence, we attempted to determine whether LIC would prove to be superior to aqueous ciprofloxacin. MATERIALS AND METHODSMice. Virus-free female BALB/cJ mice were purchased from Jackson Laboratory, Bar Harbor, Maine. Animals were housed at four to six per cage and were allowed free access to food and water. Mice weighed approximately 20 g when infected. BALB/c mice carry the itys allele, which makes them susceptible to Salmonella infections (24).Infection. S. dublin Lane pSD6 is a kanamycin-resistant derivative of the parent Lane strain in which TnS is inserted in the cryptic plasmid outside the vir region; it is fully virulent (6). Bacteria were suspended in 0.1 M NaHCO3 solution to 5 x 108 CFU/ml. A total of 0.2 ml of the suspension was delivered into the stomach by gavage. The MIC of ciprofloxacin for S. dublin was 0.03 ,ug/ml.Cultures. Organs and tissues were removed aseptically and homogenized in 2 ml of sterile saline as described previously (16 Preparation of liposomes. The liposomes consisted of dipalmitoyl-phosphatidylcholine (Avanti Polar Lipids, Inc., Alabaster, Ala.), dipalmitoyl-phosphatidylglycerol (Avanti), and cholesterol (type C-8253; Sigma Chemical Co., St. Louis, Mo.) in a molar ratio of 4.1:0.9:4. For the incorporation of ciprofloxacin into phospholipid vesicles, the dehydra-

show abstract

Section: Discussioncontrasting

confidence: 48%

“…S. dublin Lane pSD6 is a kanamycin-resistant derivative of the parent Lane strain in which TnS is inserted in the cryptic plasmid outside the vir region; it is fully virulent (6). Bacteria were suspended in 0.1 M NaHCO3 solution to 5 x 108 CFU/ml. A total of 0.2 ml of the suspension was delivered into the stomach by gavage.…”

Section: Methodsmentioning

confidence: 99%

Liposome-incorporated ciprofloxacin in treatment of murine salmonellosis

Magallanes

Dijkstra

Fierer

1993

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…In another study, topical ciprofloxacin/dexamethasone therapy was found to be superior to oral amoxicillin/clavulanic acid in acute otitis media with otorrhea 22 . Literature findings also suggest that ciprofloxacin, when given orally, is superior to ampicillin and chloramphenicol in curing typhoid in immunocompromised mice 23 . Ciprofloxacin, a commonly used broad-spectrum antibiotic, has also attracted significant interest of the scientific community due to its antiproliferative and apoptotic activities in several cancer cell lines.…”

Section: Introductionmentioning

confidence: 99%

Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects

Sharma

Jain

et al. 2010

Journal of Enzyme Inhibition and Medicinal Chemistry

248

130

View full text Add to dashboard Cite

“…In vivo pharmacokinetic studies showed that the ciprofloxacin plasma concentration was more than 2-fold increased in Bcrp1 Quinolone antimicrobial drugs are widely used because of their broad spectrum and intense bactericidal activity. They are developed for oral and parenteral use in the treatment of bacterial diseases, including severe systemic infections (Brunner and Zeiler, 1988). Most quinolone antibacterial drugs are rapidly absorbed from the intestine, with a bioavailability of close to 90%, and then penetrate well into most body tissues and fluids.…”

mentioning

confidence: 99%

“…They are developed for oral and parenteral use in the treatment of bacterial diseases, including severe systemic infections (Brunner and Zeiler, 1988). Most quinolone antibacterial drugs are rapidly absorbed from the intestine, with a bioavailability of close to 90%, and then penetrate well into most body tissues and fluids.…”

mentioning

confidence: 99%

Breast Cancer Resistance Protein (Bcrp/Abcg2) Transports Fluoroquinolone Antibiotics and Affects Their Oral Availability, Pharmacokinetics, and Milk Secretion

Álvarez²,

et al. 2006

View full text Add to dashboard Cite

ABSTRACT:The breast cancer resistance protein (BCRP/ABCG2) is an ATPbinding cassette drug efflux transporter that extrudes xenotoxins from cells in intestine, liver, mammary gland, and other organs, affecting the pharmacological and toxicological behavior of many compounds, including their secretion into the milk. The purpose of this study was to determine whether three widely used fluoroquinolone antibiotics (ciprofloxacin, ofloxacin, and norfloxacin) are substrates of Bcrp1/BCRP and to investigate the possible role of this transporter in the in vivo pharmacokinetic profile of these compounds and their secretion into the milk. Using polarized cell lines, we found that ciprofloxacin, ofloxacin, and norfloxacin are transported by mouse Bcrp1 and human BCRP. In vivo pharmacokinetic studies showed that the ciprofloxacin plasma concentration was more than 2-fold increased in Bcrp1 Quinolone antimicrobial drugs are widely used because of their broad spectrum and intense bactericidal activity. They are developed for oral and parenteral use in the treatment of bacterial diseases, including severe systemic infections (Brunner and Zeiler, 1988). Most quinolone antibacterial drugs are rapidly absorbed from the intestine, with a bioavailability of close to 90%, and then penetrate well into most body tissues and fluids. However, some fluoroquinolones have been reported to undergo efflux, which can explain the low bioavailability of some of them; for instance, the bioavailabilities of ciprofloxacin and norfloxacin are 50 to 80% and 30 to 40%, respectively (Sörgel et al., 1989;Lamp et al., 1992). In addition, at least 10% of i.v. administered ciprofloxacin is eliminated by intestinal secretion (Rohwedder et al., 1990). Only 1% of the dose is excreted into the bile (Parry et al., 1988). Some studies indicated that intestinal elimination of ciprofloxacin was not mediated by P-glycoprotein (ABCB1) (Griffiths et al., 1993;Cavet et al., 1997;Dautrey et al., 1999), one of the most important members of the ATP-binding cassette group of transporters, which is often involved in restricting the bioavailability of drugs. Accordingly, several groups (Lowes and Simmons, 2002;Michot et al., 2004) have recently shown that ciprofloxacin is not a substrate of this transporter or of MRP2 (ABCC2), another ABC transporter. However, the pharmacokinetics of ciprofloxacin was suggested to involve one or more active intestinal or hepatobiliary transport mechanisms in rats (Dautrey et al., 1999). Norfloxacin and ofloxacin have also been shown to be subject to active efflux (Cao et al., 1992;Rabbaa et al., 1996). Active secretory mechanisms common to all fluoroquinolones have been suggested (Griffiths et al., 1993(Griffiths et al., , 1994, as well as competition between fluoroquinolones at transporter sites (Rabbaa et al., 1996). However, the precise mechanisms involved in the pharmacokinetics of ciprofloxacin and other fluoroquinolones remain to be clarified.Several adverse effects have been reported with the use of quinolones, including nausea, diar...

show abstract

Oral ciprofloxacin treatment for Salmonella typhimurium infection of normal and immunocompromised mice

Cited by 18 publications

References 42 publications

Liposome-incorporated ciprofloxacin in treatment of murine salmonellosis

Liposome-incorporated ciprofloxacin in treatment of murine salmonellosis

Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects

Breast Cancer Resistance Protein (Bcrp/Abcg2) Transports Fluoroquinolone Antibiotics and Affects Their Oral Availability, Pharmacokinetics, and Milk Secretion

Contact Info

Product

Resources

About